Biosimilar HLX01 Demonstrates Bioequivalence With Rituxan in DLBCL

A new study has found that HLX01 (HanliKang), a rituximab biosimilar, had comparable overall survival and progression-free survival rates to the reference product (Rituxan) in patients with diffuse large B-cell lymphoma (DLBCL).

Related Keywords

China , ,International Prognostic Index ,China National Medical Products Administration ,World Health Organization ,Biomed Central ,National Medical Products Administration ,World Health ,Dlbcl ,Diffuse Largeb Cell Lymphoma ,Hlx01 ,Rituximab Biosimilar ,R Chop ,Th Chop ,